Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL | Zendy

Hagop M. Kantarjian | Zendy; Francis J. Giles | Zendy; Lydia Wunderle | Zendy; Kapil N. Bhalla | Zendy; Susan O’Brien | Zendy; Barbara Waßmann | Zendy; Chiaki Tanaka | Zendy; Paul W. Manley | Zendy; P. Rae | Zendy; William Mietlowski | Zendy; Kathy Bochinski | Zendy; Andreas Hochhaus | Zendy; James D. Griffin | Zendy; Dieter Hoelzer | Zendy; Maher Albitar | Zendy; Margaret Dugan | Zendy; Jorge E. Cortés | Zendy; Leila Alland | Zendy; Oliver G. Ottmann | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

Author(s) -

Hagop M. Kantarjian,

Francis J. Giles,

Lydia Wunderle,

Kapil N. Bhalla,

Susan O’Brien,

Barbara Waßmann,

Chiaki Tanaka,

Paul W. Manley,

P. Rae,

William Mietlowski,

Kathy Bochinski,

Andreas Hochhaus,

James D. Griffin,

Dieter Hoelzer,

Maher Albitar,

Margaret Dugan,

Jorge E. Cortés,

Leila Alland,

Oliver G. Ottmann

Publication year - 2006

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa055104

Subject(s) - nilotinib , medicine , imatinib , imatinib mesylate , chronic myelogenous leukemia , tyrosine kinase inhibitor , adverse effect , philadelphia chromosome , pharmacology , leukemia , gastroenterology , oncology , myeloid leukemia , cancer , chromosomal translocation , gene , biochemistry , chemistry

Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor, is more potent than imatinib against CML cells by a factor of 20 to 50.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research